Picato FDA Approval History
FDA Approved: Yes (First approved January 23, 2012)
Brand name: Picato
Generic name: ingenol mebutate
Dosage form: Topical Gel
Company: Leo Pharma
Treatment for: Keratosis
Picato (ingenol mebutate) is an inducer of cell death indicated for the topical treatment of actinic keratosis.
Development Timeline for Picato
|Jan 25, 2012||FDA Approves Picato (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.